For primary glioblastoma, bevacizumab (a humanized monoclonal antibody against VEGF-A to block angiogenesis) combined with Stupp is a currently widely used strategy which, although it prolongs the median progression-free survival, does not appear to influence the OS. The gene discussed is VEGFA; the disease is glioblastoma.